Just Published: "Patient Engagement in Orphan Drugs "

Why is the patient voice critical to orphan drug success?

Patient input is critical to an orphan drug's success, but how and when should you engage and what trends and drivers are shaping their involvement? From understanding the patient journey through better clinical trial design to post-launch support initiatives, patients are essential and knowledgeable partners for Pharma.

Informed by the insights of patient advocates and pharma, this valuable expert views report illustrates the exceptional value patient insights bring to the orphan drug development process.

"It's really important to engage with patients because they know more about their disease than anybody else."

Full Report Details at
- http://www.fastmr.com/prod/1180403_patient_engagement_orphan.aspx?afid=301

Tony Hall

Co Founder of Findacure

Reasons to Get this Report

Answering key questions:

* Understanding disease: How can pharma benefit from a deeper understanding of rare diseases through the patients' experience?
* Clinical trials: When should pharma engage with patients to ensure better clinical research outcomes?
* Engagement - but who? How can pharma effectively engage with multiple patient advocacy groups who are often pursuing different agendas?
* What do patients want? What do patients with rare diseases want from pharma and how should industry provide information and support?
* Supporting value? Can patients play an active role in supporting value claims and influencing regulatory outcomes and pricing/reimbursement decisions?
* International challenge: What are the communication and clinical research challenges when an orphan disease patient pool is widely-dispersed across many countries?

With this report you will be able to:

* Identify the new CDx approaches and evaluate their benefits.
* Understand how and where they will impact the market and review the challenges they must overcome.
* Assess the activities, policies and partnerships of CDx-progressive pharma companies.
* Understand how financial and reimbursement models need to change to reflect the real value of CDx.
* Learn how advanced CDx can radically improve clinical trial research and outcomes.
* Formulate strategies that encourage physicians to use approved CDx.
* Identify the therapy areas and conditions where next generation CDx will make an impact.
* Grasp the growing importance of research consortia in the identification of biomarkers.

Key Topics Explored:

* Pharma must engage with patient groups - but which ones? A review of patient organisations and advocacy groups in 17 countries for Duchenne Muscular Dystrophy illustrates the communication challenges for pharma in accessing rare disease patient populations.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Orphan Drugs Market 2015-2019
- Global Immunotherapy Drugs 2016-2020
- Global Gastric Cancer Drugs Market 2016-2020
- Essential ACO Engagement: Mapping New Networks of Influence
- Global Autoimmune Drugs Market 2016-2020